Клинические проявления коморбидного течения желчнокаменной болезни и неалкогольной жировой болезни печени - Журнал Терапевтический архив №8 Вопросы лечения 2020
Клинические проявления коморбидного течения желчнокаменной болезни и неалкогольной жировой болезни печени
Черкащенко Н.А., Ливзан М.А., Кролевец Т.С. Клинические проявления коморбидного течения желчнокаменной болезни и неалкогольной жировой болезни печени. Терапевтический архив. 2020; 92 (8): 29–36. DOI: 10.26442/00403660.2020.08.000764
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Цель. Для повышения эффективности ведения пациентов определить диагностическую ценность клинических особенностей коморбидного течения неалкогольной жировой болезни печени (НАЖБП) и желчнокаменной болезни (ЖКБ).
Материалы и методы. В открытое сравнительное исследование включены 183 пациента с НАЖБП. Основная группа представлена пациентами с НАЖБП и ЖКБ (n=88), из которых 53 перенесли холецистэктомию (ХЭ), группа сравнения – пациенты с НАЖБП без ЖКБ (n=95). Проведено стандартное лабораторно-инструментальное обследование, в том числе оценка стадии фиброза печени с помощью эластометрии.
Результаты. В основной группе женщин статистически достоверно больше (χ2=8,48; p≤0,01). Имелись положительные корреляционные взаимосвязи возраста пациентов, длительности течения НАЖБП с наличием ЖКБ и ХЭ (rs=0,135; p≤0,01 и rs=0,168; p≤0,01 соответственно). Общая слабость и быстрая утомляемость более часто встречались у пациентов основной группы (χ2=11,33, rs=0,234; р≤0,01 и χ2=15,68, rs=0,281; р≤0,01 соответственно), а также ощущение горечи во рту (χ2=11,66; р≤0,01; rs=0,147; р≤0,01). Среди лиц, страдающих НАЖБП и ЖКБ, чаще диагностирована ишемическая болезнь сердца (25% против 9,47% у пациентов группы сравнения; р≤0,01). Сочетание НАЖБП и ЖКБ ассоциировано с развитием сахарного диабета 2-го типа (rs=0,164; р≤0,01). У лиц с сопутствующей ЖКБ и перенесенной ХЭ отмечаются более высокие показатели липопротеидов низкой плотности и γ-глутамилтранспептидазы (rs=0,228; р≤0,01 и rs=0,298; р≤0,01 соответственно). Достоверно выше число лиц с прогрессирующими стадиями фиброза в группе ЖКБ (26,31%), особенно у лиц после ХЭ (30,18%). Стадия фиброза печени имела положительную достоверно значимую взаимосвязь с ХЭ (rs=0,366; р≤0,01).
Заключение. Коморбидное течение ЖКБ и НАЖБП клинически характеризуется симптомами диспепсии и общесоматическими жалобами. У пациентов с ЖКБ и перенесенной ХЭ установлена высокая распространенность сахарного диабета 2-го типа и ишемической болезни сердца, отмечаются более высокие показатели липопротеидов низкой плотности и γ-глутамилтранспептидазы. Перенесенная ХЭ у пациентов, страдающих ЖКБ и НАЖБП, ассоциирована с формированием прогрессирующих стадий фиброза печени.
Ключевые слова: неалкогольная жировая болезнь печени, желчнокаменная болезнь, клинические проявления, коморбидность.
Materials and methods. 183 patients with NAFLD were included into the open comparative study. The main group was represented by patients with NAFLD and GD (n=88), of which 53 patients underwent cholecystectomy (CE). The comparison group was represented by patients with NAFLD without GD (n=95). A standard laboratory and instrumental examinations were performed, including elastometry to assess of the stage of liver fibrosis.
Results. There were more women in the main group (χ2=8.48; p≤0.01). There were positive correlations between the age of patients and the duration of NAFLD with the presence of GD and CE (rs=0.135; p≤0.01 and rs=0.168; p≤0.01 respectively). Patients of the main group had the general weakness and fatigue (χ2=11.33, rs=0.234; p≤0.01 and χ2=15.68, rs=0.281; p≤0.01 respectively), as well as a bitter taste in the mouth (χ2=11.66; p≤0.01; rs=0.147; p≤0.01). Coronary heart disease was diagnosed more often among people suffering from NAFLD and GD (25% vs 9.47% in patients of the comparison group, p≤0.01). Both of NAFLD and GD were associated with the development of type 2 diabetes (rs=0.164; p≤0.01). Individuals suffering from GD after CE had higher LDL and GGT values (rs=0.228; p≤0.01 and rs=0.298; p≤0.01 respectively). The number of people with advanced fibrosis were significantly higher (26.31%) in the GD group, especially among people after CE (30.18%). The stage of liver fibrosis had a positive significant relationship with CE (rs=0.366; p≤0.01).
Conclusion. Patients suffering from GD and NAFLD had a symptom of dyspepsia and general weakness. High prevalence of type 2 diabetes and сoronary heart disease, high level of LDL and GGT were found in patients with GD and after CE. CE in patients suffering from GD and NAFLD was associated with the formation of progressive stages of liver fibrosis.
Keywords: non-alcoholic fatty liver disease, gallstone disease, clinical implications, comorbidity.
Материалы и методы. В открытое сравнительное исследование включены 183 пациента с НАЖБП. Основная группа представлена пациентами с НАЖБП и ЖКБ (n=88), из которых 53 перенесли холецистэктомию (ХЭ), группа сравнения – пациенты с НАЖБП без ЖКБ (n=95). Проведено стандартное лабораторно-инструментальное обследование, в том числе оценка стадии фиброза печени с помощью эластометрии.
Результаты. В основной группе женщин статистически достоверно больше (χ2=8,48; p≤0,01). Имелись положительные корреляционные взаимосвязи возраста пациентов, длительности течения НАЖБП с наличием ЖКБ и ХЭ (rs=0,135; p≤0,01 и rs=0,168; p≤0,01 соответственно). Общая слабость и быстрая утомляемость более часто встречались у пациентов основной группы (χ2=11,33, rs=0,234; р≤0,01 и χ2=15,68, rs=0,281; р≤0,01 соответственно), а также ощущение горечи во рту (χ2=11,66; р≤0,01; rs=0,147; р≤0,01). Среди лиц, страдающих НАЖБП и ЖКБ, чаще диагностирована ишемическая болезнь сердца (25% против 9,47% у пациентов группы сравнения; р≤0,01). Сочетание НАЖБП и ЖКБ ассоциировано с развитием сахарного диабета 2-го типа (rs=0,164; р≤0,01). У лиц с сопутствующей ЖКБ и перенесенной ХЭ отмечаются более высокие показатели липопротеидов низкой плотности и γ-глутамилтранспептидазы (rs=0,228; р≤0,01 и rs=0,298; р≤0,01 соответственно). Достоверно выше число лиц с прогрессирующими стадиями фиброза в группе ЖКБ (26,31%), особенно у лиц после ХЭ (30,18%). Стадия фиброза печени имела положительную достоверно значимую взаимосвязь с ХЭ (rs=0,366; р≤0,01).
Заключение. Коморбидное течение ЖКБ и НАЖБП клинически характеризуется симптомами диспепсии и общесоматическими жалобами. У пациентов с ЖКБ и перенесенной ХЭ установлена высокая распространенность сахарного диабета 2-го типа и ишемической болезни сердца, отмечаются более высокие показатели липопротеидов низкой плотности и γ-глутамилтранспептидазы. Перенесенная ХЭ у пациентов, страдающих ЖКБ и НАЖБП, ассоциирована с формированием прогрессирующих стадий фиброза печени.
Ключевые слова: неалкогольная жировая болезнь печени, желчнокаменная болезнь, клинические проявления, коморбидность.
________________________________________________
Materials and methods. 183 patients with NAFLD were included into the open comparative study. The main group was represented by patients with NAFLD and GD (n=88), of which 53 patients underwent cholecystectomy (CE). The comparison group was represented by patients with NAFLD without GD (n=95). A standard laboratory and instrumental examinations were performed, including elastometry to assess of the stage of liver fibrosis.
Results. There were more women in the main group (χ2=8.48; p≤0.01). There were positive correlations between the age of patients and the duration of NAFLD with the presence of GD and CE (rs=0.135; p≤0.01 and rs=0.168; p≤0.01 respectively). Patients of the main group had the general weakness and fatigue (χ2=11.33, rs=0.234; p≤0.01 and χ2=15.68, rs=0.281; p≤0.01 respectively), as well as a bitter taste in the mouth (χ2=11.66; p≤0.01; rs=0.147; p≤0.01). Coronary heart disease was diagnosed more often among people suffering from NAFLD and GD (25% vs 9.47% in patients of the comparison group, p≤0.01). Both of NAFLD and GD were associated with the development of type 2 diabetes (rs=0.164; p≤0.01). Individuals suffering from GD after CE had higher LDL and GGT values (rs=0.228; p≤0.01 and rs=0.298; p≤0.01 respectively). The number of people with advanced fibrosis were significantly higher (26.31%) in the GD group, especially among people after CE (30.18%). The stage of liver fibrosis had a positive significant relationship with CE (rs=0.366; p≤0.01).
Conclusion. Patients suffering from GD and NAFLD had a symptom of dyspepsia and general weakness. High prevalence of type 2 diabetes and сoronary heart disease, high level of LDL and GGT were found in patients with GD and after CE. CE in patients suffering from GD and NAFLD was associated with the formation of progressive stages of liver fibrosis.
Keywords: non-alcoholic fatty liver disease, gallstone disease, clinical implications, comorbidity.
Список литературы
1. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl.):S47-64. doi: 10.1016/j.jhep.2014.12.012
2. Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97:e0214. doi: 10.1097/MD.0000000000010214
3. Abdeldyem SM, Goda T, Khodeir SA, et al. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J ClinLipidol. 2017;11:915-9. doi: 10.1016/j.jacl.2017.04.115
4. Черкащенко Н.А., Ливзан М.А., Гаус О.В., Кролевец Т.С. Неалкогольная жировая болезнь печени и желчнокаменная болезнь: случайное или закономерное сочетание? Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019;3:40-4 [Cherkashchenko NA, Livzan MA, Gaus OV, Krolevets TS. Non-alcoholic fatty liver disease and cholelithiasis: a random or regular combination? Gastroenterology. Surgery. Intensive care. Consilium Medicum. 2019;3:40-4 (In Russ.)]. doi: 10.26442/26583739.2019.3.190489
5. Henson JB, Simon TG, Kaplan A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51(7):728-36. doi: 10.1111/apt.15660
6. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Translat Hepatol. 2017;5:384-93. doi: 10.14218/JCTH.2017.00013
7. Кролевец Т.С., Ливзан М.А. Клинико-лабораторные маркеры прогнозирования фиброза печени у лиц с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2018;155(7):43-51 [Krolevets TS, Livzan MA. Clinical and laboratory markers for predicting liver fibrosis in individuals with nonalcoholic fatty liver disease. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2018;155(7):43-51 (In Russ.)]. eLIBRARY ID: 38200880
8. Ливзан М.А., Лаптева И.В., Кролевец Т.С., Черкащенко Н.А. Лептинорезистентность у пациентов с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. Мед. совет. 2015;13:58-63 [Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Medical Council. 2015;13:58-63 (In Russ.)]. doi: 10.21518/2079-701X2015-13-58-63
9. Da Zhou, Jian-Gao Fan. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(17):2019-28. doi: 10.3748/wjg.v25.i17.2019
10. Краснер Я.А., Осипенко М.Ф., Валуйских Е.Ю. и др. Частота и особенности неалкогольного стеатогепатоза/стеатогепатита у пациентов с воспалительными заболеваниями кишечника. Journal of Siberian Medical Sciences. 2019;3:63-73 [Krasner YaA, Osipenko MF, Valuyskikh EYu, et al. Frequency and features of non-alcoholic fatty liver disease/steatohepatitis in patients with inflammatory bowel disease. Journal of Siberian Medical Sciences. 2019;3:63-73 (In Russ.)].
11. Ливзан М.А., Гаус О.В., Николаев Н.А., Кролевец Т.С. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019;170(10):57-65 [Livzan MA, Gaus OV, Nikolaev NA, Krolevetz TS. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;170(10): 57-65 (In Russ.)]. doi: 10.31146/1682-8658-ecg-170-10-57-65
12. Jaruvongvanich V, Sanguankeo A, Upala S. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Digest Dis Sci. 2016;61:2389-96. doi: 10.1007/s10620-016-4125-2
13. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. June 2012. http://www.worldgastroenterology.org/NAFLD-NASH.html
14. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-31. doi: 10.1053/j.gastro.2010.09.038
15. Ивашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. РЖГГК. 2015;6:31-41 [Ivashkin VT, Drapkina OM, Mayev IV, et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. RZHGGK. 2015;6:31-41 (In Russ.)].
16. Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024.
17. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19(45):8301-11. doi: 10.3748/wjg.v19.i45.8301
18. Дичева Д.Т., Кузнецова Е.И. Современные аспекты лечения пациентов с неалкогольной жировой болезнью печени. Consilium Medicum. 2018;20(8):20-3 [Dicheva DT, Kuznetsova EI. Modern aspects of nonalcoholic fatty liver disease patients treatment. Consilium Medicum. 2018;20(8):20-3 (In Russ.)]. doi: 10.26442/2075-1753_2018.8.20-23
19. Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology. 2011;140:508-16. doi: 10.1053/j.gastro.2010.10.060
20. Черкащенко Н.А., Ливзан М.А., Кролевец Т.С. Особенности течения желчнокаменной болезни у пациентов, страдающих неалкогольной жировой болезнью печени. Терапевтический архив. 2020;92(2):48-54 [Cherkashchenko NA, Livzan MA, Krolevets TS. Features of the course of gallstone disease in patients with non-alcoholic fatty liver disease. Therapeutic Archive. 2020;92(2):48-54 (In Russ.)]. doi: 10.26442/00403660.2020.02.000550
21. Koller T, Kollerova J, Hlavaty T, et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012;47:197-203. doi: 10.3109/00365521.2011.643481
22. Loria P, Lonardo A, Lombardini S, et al. Gallstone disease in nonalcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol. 2005;20:1176-84. doi: 10.1111/j.1440-1746.2005.03924.x
23. Liu J, Lin H, Zhang C, et al. Nonalcoholic fatty liver disease associated with gallstones in females rather than males: a longitudinal cohort study in Chinese urban population. BMC Gastroenterol. 2014;14:213. doi: 10.1186/s12876-014-0213-y
24. Lin IC, Yang YW, Wu MF, et al. The association of metabolic syndrome and its factors with gallstone disease. BMC Fam Pract. 2014;15:138. doi: 10.1186/1471-2296-15-138
25. Yongsheng Chen, Shuodong Wu, Yu Tian. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. Lab Invest. 2018;98:7-14. doi: 10.1038/labinvest.2017.95
26. Ata N, Kucukazman M, Yavuz B, et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol. 2011;25:274-6. doi: 10.1155/2011/356761
27. Shen C, Wu X, Xu C, et al. Association of cholecystectomy with metabolic syndrome in a Chinese population. PLoS ONE. 2014;9:e88189. doi: 10.1371/journal.pone.0088189
28. Ивашкин В.Т., Маев И.В., Баранская Е.К. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению желчнокаменной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016;26(3):64-80 [Ivashkin VT, Mayev IV, Baranskaya YeK, et al. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):64-80 (In Russ.)]. doi: 10.22416/1382-4376-2016-26-3-64-80
29. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr. 2004;80:38-44. doi: 10.1093/ajcn/80.1.38
30. Макарова Ю.В., Осипенко М.Ф., Литвинова Н.В., Волошина Н.Б. Гастроинтестинальные симптомы у больных желчнокаменной болезнью в динамике 10-летнего наблюдения. Экспериментальная и клиническая гастроэнтерология. 2018;155(7):30-6 [Makarova YV, Osipen-
ko MF, Litvinova NV, Voloshina NB. Gastrointestinal symptoms in patients with gilt-patient disease in the dynamics of 10-year observation. Experimental and Clinical Gastroenterology. 2018;155(7):30-6 (In Russ.)].
31. Лебедева О.В., Буеверов А.О., Буеверова Е.Л., Никитина Л.О. Влияние холецистэктомии в молодом возрасте на течение метаболического синдрома у женщин. Альманах клин. медицины. 2017;45(5):384-91 [Lebedeva OV, Bueverov AO, Bueverova EL, Nikitina LO. The influence of cholecystectomy at young age on the course of metabolic syndrome in women. Almanac of Clinical Medicine. 2017;45(5):384-91 (In Russ.)]. doi: 10.18786/2072-0505-2017-45-5-384-391
32. Keren N, Konikoff FM, Paitan Y, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ Microbiol Rep. 2015;7:874-80. doi: 10.1111/1758-2229.12319
33. Fracanzani AL, Valenti L, Russello M, et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2012;7(7):e41183. doi: 10.1371/
journal.pone.0041183
34. Bodmer M, Brauchli YB, Jick SS, Meier CR Diabetes mellitus and the risk of cholecystectomy. Dig Liver Dis. 2011;43:742-7. doi: 10.1016/j.dld.2011.04.014
35. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834-8. doi: 10.2337/dc08-1755
36. Lailai Fan, Baihui Chen, Zhijuan Dai. The relation between gallstone disease and cardiovascular disease. Sci Reports. 2017;7:15104. doi: 10.1038/s41598-017-15430-5
37. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology. 2009;136:1593-600. doi: 10.1053/j.gastro.2009.01.042
38. Desai CS, Martin SS, Blumenthal RS, Ciccarone JH. Non-cardiovascular effects associated with statins. BMJ. 2014;349:g3743. doi: 10.1136/bmj.g3743:10.1136/bmj.g3743
39. Буеверов А.О. Клинико-патогенетические параллели неалкогольной жировой болезни печени и желчнокаменной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):17-23 [Bueverov AO. Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):17-23 (In Russ.)]. doi: 10.22416/1382-4376-2019-29-1-17-23
40. Ахмедов В.А., Гаус О.В. Современные представления о механизмах развития и тактике ведения больных желчнокаменной болезнью, ассоциированной с метаболическим синдромом. Мед. алфавит. 2019;2(13):52-6 [Akhmedov VA, Gaus OV. Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome. Medical Alphabet. 2019;2(13):52-6 (In Russ.)]. doi: 10.33667/2078-5631-2019-2-13(388)-52-56
41. Yilmaz Y, Ayyildiz T, Akin H, et al. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. Gut Liver. 2014;8(3):313-7. doi: 10.5009/gnl.2014.8.3.313
42. Yoosoo Chang, Yoo-Hun Noh, Byung-Seong Suh, et al. Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. J Clin Med. 2018;7:458. doi: 10.3390/jcm7110458
43. Yun S, Choi D, Lee KG, et al. Cholecystectomy causes ultrasound evidence of increased hepatic steatosis. World J Surg. 2016;40:1412-21. doi: 10.1007/s00268-015-3396-7
44. Kwak MS, Kim D, Chung GE, et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol. 2015;21:6287-95. doi: 10.3748/wjg.v21.i20.6287
2. Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97:e0214. doi: 10.1097/MD.0000000000010214
3. Abdeldyem SM, Goda T, Khodeir SA, et al. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J ClinLipidol. 2017;11:915-9. doi: 10.1016/j.jacl.2017.04.115
4. Cherkashchenko NA, Livzan MA, Gaus OV, Krolevets TS. Non-alcoholic fatty liver disease and cholelithiasis: a random or regular combination? Gastroenterology. Surgery. Intensive care. Consilium Medicum. 2019;3:40-4 (In Russ.) doi: 10.26442/26583739.2019.3.190489
5. Henson JB, Simon TG, Kaplan A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51(7):728-36. doi: 10.1111/apt.15660
6. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Translat Hepatol. 2017;5:384-93. doi: 10.14218/JCTH.2017.00013
7. Krolevets TS, Livzan MA. Clinical and laboratory markers for predicting liver fibrosis in individuals with nonalcoholic fatty liver disease. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2018;155(7):43-51 (In Russ.) eLIBRARY ID: 38200880
8. Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Medical Council. 2015;13:58-63 (In Russ.)] doi: 10.21518/2079-701X2015-13-58-63
9. Da Zhou, Jian-Gao Fan. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(17):2019-28. doi: 10.3748/wjg.v25.i17.2019
10. Krasner YaA, Osipenko MF, Valuyskikh EYu, et al. Frequency and features of non-alcoholic fatty liver disease/steatohepatitis in patients with inflammatory bowel disease. Journal of Siberian Medical Sciences. 2019;3:63-73 (In Russ.)
11. Livzan MA, Gaus OV, Nikolaev NA, Krolevetz TS. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;170(10): 57-65 (In Russ.) doi: 10.31146/1682-8658-ecg-170-10-57-65
12. Jaruvongvanich V, Sanguankeo A, Upala S. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Digest Dis Sci. 2016;61:2389-96. doi: 10.1007/s10620-016-4125-2
13. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. June 2012. http://www.worldgastroenterology.org/NAFLD-NASH.html
14. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-31. doi: 10.1053/j.gastro.2010.09.038
15. Ivashkin VT, Drapkina OM, Mayev IV, et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. RZHGGK. 2015;6:31-41 (In Russ.)
16. Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024.
17. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19(45):8301-11. doi: 10.3748/wjg.v19.i45.8301
18. Dicheva DT, Kuznetsova EI. Modern aspects of nonalcoholic fatty liver disease patients treatment. Consilium Medicum. 2018;20(8):20-3 (In Russ.) doi: 10.26442/2075-1753_2018.8.20-23
19. Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology. 2011;140:508-16. doi: 10.1053/j.gastro.2010.10.060
20. Cherkashchenko NA, Livzan MA, Krolevets TS. Features of the course of gallstone disease in patients with non-alcoholic fatty liver disease. Therapeutic Archive. 2020;92(2):48-54 (In Russ.) doi: 10.26442/00403660.2020.02.000550
21. Koller T, Kollerova J, Hlavaty T, et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012;47:197-203. doi: 10.3109/00365521.2011.643481
22. Loria P, Lonardo A, Lombardini S, et al. Gallstone disease in nonalcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol. 2005;20:1176-84. doi: 10.1111/j.1440-1746.2005.03924.x
23. Liu J, Lin H, Zhang C, et al. Nonalcoholic fatty liver disease associated with gallstones in females rather than males: a longitudinal cohort study in Chinese urban population. BMC Gastroenterol. 2014;14:213. doi: 10.1186/s12876-014-0213-y
24. Lin IC, Yang YW, Wu MF, et al. The association of metabolic syndrome and its factors with gallstone disease. BMC Fam Pract. 2014;15:138. doi: 10.1186/1471-2296-15-138
25. Yongsheng Chen, Shuodong Wu, Yu Tian. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. Lab Invest. 2018;98:7-14. doi: 10.1038/labinvest.2017.95
26. Ata N, Kucukazman M, Yavuz B, et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol. 2011;25:274-6. doi: 10.1155/2011/356761
27. Shen C, Wu X, Xu C, et al. Association of cholecystectomy with metabolic syndrome in a Chinese population. PLoS ONE. 2014;9:e88189. doi: 10.1371/journal.pone.0088189
28. Ivashkin VT, Mayev IV, Baranskaya YeK, et al. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):64-80 (In Russ.) doi: 10.22416/1382-4376-2016-26-3-64-80
29. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr. 2004;80:38-44. doi: 10.1093/ajcn/80.1.38
30. Makarova YV, Osipenko MF, Litvinova NV, Voloshina NB. Gastrointestinal symptoms in patients with gilt-patient disease in the dynamics of 10-year observation. Experimental and Clinical Gastroenterology. 2018;155(7):30-6 (In Russ.)
31. Lebedeva OV, Bueverov AO, Bueverova EL, Nikitina LO. The influence of cholecystectomy at young age on the course of metabolic syndrome in women. Almanac of Clinical Medicine. 2017;45(5):384-91 (In Russ.) doi: 10.18786/2072-0505-2017-45-5-384-391
32. Keren N, Konikoff FM, Paitan Y, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ Microbiol Rep. 2015;7:874-80. doi: 10.1111/1758-2229.12319
33. Fracanzani AL, Valenti L, Russello M, et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2012;7(7):e41183. doi: 10.1371/
journal.pone.0041183
34. Bodmer M, Brauchli YB, Jick SS, Meier CR Diabetes mellitus and the risk of cholecystectomy. Dig Liver Dis. 2011;43:742-7. doi: 10.1016/j.dld.2011.04.014
35. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834-8. doi: 10.2337/dc08-1755
36. Lailai Fan, Baihui Chen, Zhijuan Dai. The relation between gallstone disease and cardiovascular disease. Sci Reports. 2017;7:15104. doi: 10.1038/s41598-017-15430-5
37. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology. 2009;136:1593-600. doi: 10.1053/j.gastro.2009.01.042
38. Desai CS, Martin SS, Blumenthal RS, Ciccarone JH. Non-cardiovascular effects associated with statins. BMJ. 2014;349:g3743. doi: 10.1136/bmj.g3743:10.1136/bmj.g3743
39. Bueverov AO. Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):17-23 (In Russ.) doi: 10.22416/1382-4376-2019-29-1-17-23
40. Akhmedov VA, Gaus OV. Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome. Medical Alphabet. 2019;2(13):52-6 (In Russ.) doi: 10.33667/2078-5631-2019-2-13(388)-52-56
41. Yilmaz Y, Ayyildiz T, Akin H, et al. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. Gut Liver. 2014;8(3):313-7. doi: 10.5009/gnl.2014.8.3.313
42. Yoosoo Chang, Yoo-Hun Noh, Byung-Seong Suh, et al. Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. J Clin Med. 2018;7:458. doi: 10.3390/jcm7110458
43. Yun S, Choi D, Lee KG, et al. Cholecystectomy causes ultrasound evidence of increased hepatic steatosis. World J Surg. 2016;40:1412-21. doi: 10.1007/s00268-015-3396-7
44. Kwak MS, Kim D, Chung GE, et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol. 2015;21:6287-95. doi: 10.3748/wjg.v21.i20.6287
2. Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97:e0214. doi: 10.1097/MD.0000000000010214
3. Abdeldyem SM, Goda T, Khodeir SA, et al. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J ClinLipidol. 2017;11:915-9. doi: 10.1016/j.jacl.2017.04.115
4. Черкащенко Н.А., Ливзан М.А., Гаус О.В., Кролевец Т.С. Неалкогольная жировая болезнь печени и желчнокаменная болезнь: случайное или закономерное сочетание? Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019;3:40-4 [Cherkashchenko NA, Livzan MA, Gaus OV, Krolevets TS. Non-alcoholic fatty liver disease and cholelithiasis: a random or regular combination? Gastroenterology. Surgery. Intensive care. Consilium Medicum. 2019;3:40-4 (In Russ.)]. doi: 10.26442/26583739.2019.3.190489
5. Henson JB, Simon TG, Kaplan A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51(7):728-36. doi: 10.1111/apt.15660
6. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Translat Hepatol. 2017;5:384-93. doi: 10.14218/JCTH.2017.00013
7. Кролевец Т.С., Ливзан М.А. Клинико-лабораторные маркеры прогнозирования фиброза печени у лиц с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2018;155(7):43-51 [Krolevets TS, Livzan MA. Clinical and laboratory markers for predicting liver fibrosis in individuals with nonalcoholic fatty liver disease. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2018;155(7):43-51 (In Russ.)]. eLIBRARY ID: 38200880
8. Ливзан М.А., Лаптева И.В., Кролевец Т.С., Черкащенко Н.А. Лептинорезистентность у пациентов с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. Мед. совет. 2015;13:58-63 [Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Medical Council. 2015;13:58-63 (In Russ.)]. doi: 10.21518/2079-701X2015-13-58-63
9. Da Zhou, Jian-Gao Fan. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(17):2019-28. doi: 10.3748/wjg.v25.i17.2019
10. Краснер Я.А., Осипенко М.Ф., Валуйских Е.Ю. и др. Частота и особенности неалкогольного стеатогепатоза/стеатогепатита у пациентов с воспалительными заболеваниями кишечника. Journal of Siberian Medical Sciences. 2019;3:63-73 [Krasner YaA, Osipenko MF, Valuyskikh EYu, et al. Frequency and features of non-alcoholic fatty liver disease/steatohepatitis in patients with inflammatory bowel disease. Journal of Siberian Medical Sciences. 2019;3:63-73 (In Russ.)].
11. Ливзан М.А., Гаус О.В., Николаев Н.А., Кролевец Т.С. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019;170(10):57-65 [Livzan MA, Gaus OV, Nikolaev NA, Krolevetz TS. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;170(10): 57-65 (In Russ.)]. doi: 10.31146/1682-8658-ecg-170-10-57-65
12. Jaruvongvanich V, Sanguankeo A, Upala S. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Digest Dis Sci. 2016;61:2389-96. doi: 10.1007/s10620-016-4125-2
13. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. June 2012. http://www.worldgastroenterology.org/NAFLD-NASH.html
14. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-31. doi: 10.1053/j.gastro.2010.09.038
15. Ивашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. РЖГГК. 2015;6:31-41 [Ivashkin VT, Drapkina OM, Mayev IV, et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. RZHGGK. 2015;6:31-41 (In Russ.)].
16. Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024.
17. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19(45):8301-11. doi: 10.3748/wjg.v19.i45.8301
18. Дичева Д.Т., Кузнецова Е.И. Современные аспекты лечения пациентов с неалкогольной жировой болезнью печени. Consilium Medicum. 2018;20(8):20-3 [Dicheva DT, Kuznetsova EI. Modern aspects of nonalcoholic fatty liver disease patients treatment. Consilium Medicum. 2018;20(8):20-3 (In Russ.)]. doi: 10.26442/2075-1753_2018.8.20-23
19. Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology. 2011;140:508-16. doi: 10.1053/j.gastro.2010.10.060
20. Черкащенко Н.А., Ливзан М.А., Кролевец Т.С. Особенности течения желчнокаменной болезни у пациентов, страдающих неалкогольной жировой болезнью печени. Терапевтический архив. 2020;92(2):48-54 [Cherkashchenko NA, Livzan MA, Krolevets TS. Features of the course of gallstone disease in patients with non-alcoholic fatty liver disease. Therapeutic Archive. 2020;92(2):48-54 (In Russ.)]. doi: 10.26442/00403660.2020.02.000550
21. Koller T, Kollerova J, Hlavaty T, et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012;47:197-203. doi: 10.3109/00365521.2011.643481
22. Loria P, Lonardo A, Lombardini S, et al. Gallstone disease in nonalcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol. 2005;20:1176-84. doi: 10.1111/j.1440-1746.2005.03924.x
23. Liu J, Lin H, Zhang C, et al. Nonalcoholic fatty liver disease associated with gallstones in females rather than males: a longitudinal cohort study in Chinese urban population. BMC Gastroenterol. 2014;14:213. doi: 10.1186/s12876-014-0213-y
24. Lin IC, Yang YW, Wu MF, et al. The association of metabolic syndrome and its factors with gallstone disease. BMC Fam Pract. 2014;15:138. doi: 10.1186/1471-2296-15-138
25. Yongsheng Chen, Shuodong Wu, Yu Tian. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. Lab Invest. 2018;98:7-14. doi: 10.1038/labinvest.2017.95
26. Ata N, Kucukazman M, Yavuz B, et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol. 2011;25:274-6. doi: 10.1155/2011/356761
27. Shen C, Wu X, Xu C, et al. Association of cholecystectomy with metabolic syndrome in a Chinese population. PLoS ONE. 2014;9:e88189. doi: 10.1371/journal.pone.0088189
28. Ивашкин В.Т., Маев И.В., Баранская Е.К. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению желчнокаменной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016;26(3):64-80 [Ivashkin VT, Mayev IV, Baranskaya YeK, et al. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):64-80 (In Russ.)]. doi: 10.22416/1382-4376-2016-26-3-64-80
29. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr. 2004;80:38-44. doi: 10.1093/ajcn/80.1.38
30. Макарова Ю.В., Осипенко М.Ф., Литвинова Н.В., Волошина Н.Б. Гастроинтестинальные симптомы у больных желчнокаменной болезнью в динамике 10-летнего наблюдения. Экспериментальная и клиническая гастроэнтерология. 2018;155(7):30-6 [Makarova YV, Osipen-
ko MF, Litvinova NV, Voloshina NB. Gastrointestinal symptoms in patients with gilt-patient disease in the dynamics of 10-year observation. Experimental and Clinical Gastroenterology. 2018;155(7):30-6 (In Russ.)].
31. Лебедева О.В., Буеверов А.О., Буеверова Е.Л., Никитина Л.О. Влияние холецистэктомии в молодом возрасте на течение метаболического синдрома у женщин. Альманах клин. медицины. 2017;45(5):384-91 [Lebedeva OV, Bueverov AO, Bueverova EL, Nikitina LO. The influence of cholecystectomy at young age on the course of metabolic syndrome in women. Almanac of Clinical Medicine. 2017;45(5):384-91 (In Russ.)]. doi: 10.18786/2072-0505-2017-45-5-384-391
32. Keren N, Konikoff FM, Paitan Y, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ Microbiol Rep. 2015;7:874-80. doi: 10.1111/1758-2229.12319
33. Fracanzani AL, Valenti L, Russello M, et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2012;7(7):e41183. doi: 10.1371/
journal.pone.0041183
34. Bodmer M, Brauchli YB, Jick SS, Meier CR Diabetes mellitus and the risk of cholecystectomy. Dig Liver Dis. 2011;43:742-7. doi: 10.1016/j.dld.2011.04.014
35. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834-8. doi: 10.2337/dc08-1755
36. Lailai Fan, Baihui Chen, Zhijuan Dai. The relation between gallstone disease and cardiovascular disease. Sci Reports. 2017;7:15104. doi: 10.1038/s41598-017-15430-5
37. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology. 2009;136:1593-600. doi: 10.1053/j.gastro.2009.01.042
38. Desai CS, Martin SS, Blumenthal RS, Ciccarone JH. Non-cardiovascular effects associated with statins. BMJ. 2014;349:g3743. doi: 10.1136/bmj.g3743:10.1136/bmj.g3743
39. Буеверов А.О. Клинико-патогенетические параллели неалкогольной жировой болезни печени и желчнокаменной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):17-23 [Bueverov AO. Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):17-23 (In Russ.)]. doi: 10.22416/1382-4376-2019-29-1-17-23
40. Ахмедов В.А., Гаус О.В. Современные представления о механизмах развития и тактике ведения больных желчнокаменной болезнью, ассоциированной с метаболическим синдромом. Мед. алфавит. 2019;2(13):52-6 [Akhmedov VA, Gaus OV. Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome. Medical Alphabet. 2019;2(13):52-6 (In Russ.)]. doi: 10.33667/2078-5631-2019-2-13(388)-52-56
41. Yilmaz Y, Ayyildiz T, Akin H, et al. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. Gut Liver. 2014;8(3):313-7. doi: 10.5009/gnl.2014.8.3.313
42. Yoosoo Chang, Yoo-Hun Noh, Byung-Seong Suh, et al. Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. J Clin Med. 2018;7:458. doi: 10.3390/jcm7110458
43. Yun S, Choi D, Lee KG, et al. Cholecystectomy causes ultrasound evidence of increased hepatic steatosis. World J Surg. 2016;40:1412-21. doi: 10.1007/s00268-015-3396-7
44. Kwak MS, Kim D, Chung GE, et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol. 2015;21:6287-95. doi: 10.3748/wjg.v21.i20.6287
________________________________________________
2. Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97:e0214. doi: 10.1097/MD.0000000000010214
3. Abdeldyem SM, Goda T, Khodeir SA, et al. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J ClinLipidol. 2017;11:915-9. doi: 10.1016/j.jacl.2017.04.115
4. Cherkashchenko NA, Livzan MA, Gaus OV, Krolevets TS. Non-alcoholic fatty liver disease and cholelithiasis: a random or regular combination? Gastroenterology. Surgery. Intensive care. Consilium Medicum. 2019;3:40-4 (In Russ.) doi: 10.26442/26583739.2019.3.190489
5. Henson JB, Simon TG, Kaplan A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51(7):728-36. doi: 10.1111/apt.15660
6. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Translat Hepatol. 2017;5:384-93. doi: 10.14218/JCTH.2017.00013
7. Krolevets TS, Livzan MA. Clinical and laboratory markers for predicting liver fibrosis in individuals with nonalcoholic fatty liver disease. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2018;155(7):43-51 (In Russ.) eLIBRARY ID: 38200880
8. Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Medical Council. 2015;13:58-63 (In Russ.)] doi: 10.21518/2079-701X2015-13-58-63
9. Da Zhou, Jian-Gao Fan. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(17):2019-28. doi: 10.3748/wjg.v25.i17.2019
10. Krasner YaA, Osipenko MF, Valuyskikh EYu, et al. Frequency and features of non-alcoholic fatty liver disease/steatohepatitis in patients with inflammatory bowel disease. Journal of Siberian Medical Sciences. 2019;3:63-73 (In Russ.)
11. Livzan MA, Gaus OV, Nikolaev NA, Krolevetz TS. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;170(10): 57-65 (In Russ.) doi: 10.31146/1682-8658-ecg-170-10-57-65
12. Jaruvongvanich V, Sanguankeo A, Upala S. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Digest Dis Sci. 2016;61:2389-96. doi: 10.1007/s10620-016-4125-2
13. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. June 2012. http://www.worldgastroenterology.org/NAFLD-NASH.html
14. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-31. doi: 10.1053/j.gastro.2010.09.038
15. Ivashkin VT, Drapkina OM, Mayev IV, et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. RZHGGK. 2015;6:31-41 (In Russ.)
16. Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024.
17. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19(45):8301-11. doi: 10.3748/wjg.v19.i45.8301
18. Dicheva DT, Kuznetsova EI. Modern aspects of nonalcoholic fatty liver disease patients treatment. Consilium Medicum. 2018;20(8):20-3 (In Russ.) doi: 10.26442/2075-1753_2018.8.20-23
19. Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology. 2011;140:508-16. doi: 10.1053/j.gastro.2010.10.060
20. Cherkashchenko NA, Livzan MA, Krolevets TS. Features of the course of gallstone disease in patients with non-alcoholic fatty liver disease. Therapeutic Archive. 2020;92(2):48-54 (In Russ.) doi: 10.26442/00403660.2020.02.000550
21. Koller T, Kollerova J, Hlavaty T, et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012;47:197-203. doi: 10.3109/00365521.2011.643481
22. Loria P, Lonardo A, Lombardini S, et al. Gallstone disease in nonalcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol. 2005;20:1176-84. doi: 10.1111/j.1440-1746.2005.03924.x
23. Liu J, Lin H, Zhang C, et al. Nonalcoholic fatty liver disease associated with gallstones in females rather than males: a longitudinal cohort study in Chinese urban population. BMC Gastroenterol. 2014;14:213. doi: 10.1186/s12876-014-0213-y
24. Lin IC, Yang YW, Wu MF, et al. The association of metabolic syndrome and its factors with gallstone disease. BMC Fam Pract. 2014;15:138. doi: 10.1186/1471-2296-15-138
25. Yongsheng Chen, Shuodong Wu, Yu Tian. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. Lab Invest. 2018;98:7-14. doi: 10.1038/labinvest.2017.95
26. Ata N, Kucukazman M, Yavuz B, et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol. 2011;25:274-6. doi: 10.1155/2011/356761
27. Shen C, Wu X, Xu C, et al. Association of cholecystectomy with metabolic syndrome in a Chinese population. PLoS ONE. 2014;9:e88189. doi: 10.1371/journal.pone.0088189
28. Ivashkin VT, Mayev IV, Baranskaya YeK, et al. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):64-80 (In Russ.) doi: 10.22416/1382-4376-2016-26-3-64-80
29. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr. 2004;80:38-44. doi: 10.1093/ajcn/80.1.38
30. Makarova YV, Osipenko MF, Litvinova NV, Voloshina NB. Gastrointestinal symptoms in patients with gilt-patient disease in the dynamics of 10-year observation. Experimental and Clinical Gastroenterology. 2018;155(7):30-6 (In Russ.)
31. Lebedeva OV, Bueverov AO, Bueverova EL, Nikitina LO. The influence of cholecystectomy at young age on the course of metabolic syndrome in women. Almanac of Clinical Medicine. 2017;45(5):384-91 (In Russ.) doi: 10.18786/2072-0505-2017-45-5-384-391
32. Keren N, Konikoff FM, Paitan Y, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ Microbiol Rep. 2015;7:874-80. doi: 10.1111/1758-2229.12319
33. Fracanzani AL, Valenti L, Russello M, et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2012;7(7):e41183. doi: 10.1371/
journal.pone.0041183
34. Bodmer M, Brauchli YB, Jick SS, Meier CR Diabetes mellitus and the risk of cholecystectomy. Dig Liver Dis. 2011;43:742-7. doi: 10.1016/j.dld.2011.04.014
35. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834-8. doi: 10.2337/dc08-1755
36. Lailai Fan, Baihui Chen, Zhijuan Dai. The relation between gallstone disease and cardiovascular disease. Sci Reports. 2017;7:15104. doi: 10.1038/s41598-017-15430-5
37. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology. 2009;136:1593-600. doi: 10.1053/j.gastro.2009.01.042
38. Desai CS, Martin SS, Blumenthal RS, Ciccarone JH. Non-cardiovascular effects associated with statins. BMJ. 2014;349:g3743. doi: 10.1136/bmj.g3743:10.1136/bmj.g3743
39. Bueverov AO. Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):17-23 (In Russ.) doi: 10.22416/1382-4376-2019-29-1-17-23
40. Akhmedov VA, Gaus OV. Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome. Medical Alphabet. 2019;2(13):52-6 (In Russ.) doi: 10.33667/2078-5631-2019-2-13(388)-52-56
41. Yilmaz Y, Ayyildiz T, Akin H, et al. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. Gut Liver. 2014;8(3):313-7. doi: 10.5009/gnl.2014.8.3.313
42. Yoosoo Chang, Yoo-Hun Noh, Byung-Seong Suh, et al. Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. J Clin Med. 2018;7:458. doi: 10.3390/jcm7110458
43. Yun S, Choi D, Lee KG, et al. Cholecystectomy causes ultrasound evidence of increased hepatic steatosis. World J Surg. 2016;40:1412-21. doi: 10.1007/s00268-015-3396-7
44. Kwak MS, Kim D, Chung GE, et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol. 2015;21:6287-95. doi: 10.3748/wjg.v21.i20.6287
Авторы
Н.А. Черкащенко1, М.А. Ливзан2, Т.С. Кролевец2
1 ФГБУЗ «Западно-Сибирский медицинский центр» ФМБА России, Омск, Россия;
2 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
1 West Siberian Medical Center, Omsk, Russia;
2 Omsk State Medical University, Omsk, Russia
1 ФГБУЗ «Западно-Сибирский медицинский центр» ФМБА России, Омск, Россия;
2 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
________________________________________________
1 West Siberian Medical Center, Omsk, Russia;
2 Omsk State Medical University, Omsk, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.